These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19538067)

  • 21. Clinical failures of linezolid and implications for the clinical microbiology laboratory.
    Potoski BA; Mangino JE; Goff DA
    Emerg Infect Dis; 2002 Dec; 8(12):1519-20. PubMed ID: 12498678
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel antibacterial agents for skin and skin structure infections.
    Schweiger ES; Weinberg JM
    J Am Acad Dermatol; 2004 Mar; 50(3):331-40; quiz 341-2. PubMed ID: 14988672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes by methicillin-resistant Staphylococcus aureus staphylococcal cassette chromosome mec type: isolates recovered from a phase IV clinical trial of linezolid and vancomycin for complicated skin and skin structure infections.
    Huang DB; Reisman A; Hogan P
    Antimicrob Agents Chemother; 2010 Sep; 54(9):4036-7. PubMed ID: 20585131
    [No Abstract]   [Full Text] [Related]  

  • 24. Persistent methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia due to a linezolid "tolerant" strain.
    Cunha BA; Nausheen S; Schoch P
    Heart Lung; 2010; 39(2):173-5. PubMed ID: 20207279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias.
    Melzer M; Goldsmith D; Gransden W
    Clin Infect Dis; 2000 Jul; 31(1):208-9. PubMed ID: 10913433
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?
    Howden BP; Charles PG; Johnson PD; Ward PB; Grayson ML
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4816; author reply 4816-7. PubMed ID: 16251343
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid.
    Plouffe JF
    Clin Infect Dis; 2000 Sep; 31 Suppl 4():S144-9. PubMed ID: 11017864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of linezolid in children: an overview of recent advances.
    Velissariou IM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
    Weigelt J; Itani K; Stevens D; Lau W; Dryden M; Knirsch C;
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2260-6. PubMed ID: 15917519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections.
    Hau T
    Eur J Clin Microbiol Infect Dis; 2002 Jul; 21(7):491-8. PubMed ID: 12172739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.
    Stevens DL; Smith LG; Bruss JB; McConnell-Martin MA; Duvall SE; Todd WM; Hafkin B
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3408-13. PubMed ID: 11083648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid.
    Balkhair A; Al Muharrmi Z; Darwish L; Farhan H; Sallam M
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e227-9. PubMed ID: 20005763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with Gram-negative bacteremia.
    Ternavasio-de la Vega HG; Mateos-Díaz AM; Martinez JA; Almela M; Cobos-Trigueros N; Morata L; De-la-Calle C; Sala M; Mensa J; Marcos M; Soriano A
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7025-31. PubMed ID: 25199780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
    Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
    J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.
    Chuang YC; Wang JT; Lin HY; Chang SC
    BMC Infect Dis; 2014 Dec; 14():687. PubMed ID: 25495779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?
    Kalil AC; Puumala S; Stoner J
    Antimicrob Agents Chemother; 2006 May; 50(5):1910; author reply 1910-1. PubMed ID: 16641477
    [No Abstract]   [Full Text] [Related]  

  • 37. Enterococcal bacteremia complicating pemphigus vulgaris: successful treatment with linezolid.
    Garg G; Thami GP
    J Dermatol; 2004 Jul; 31(7):580-1. PubMed ID: 15492427
    [No Abstract]   [Full Text] [Related]  

  • 38. Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient.
    Arena F; Giani T; Galano A; Pasculli M; Peccianti V; Cassetta MI; Novelli A; Rossolini GM
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6411-2. PubMed ID: 24222608
    [No Abstract]   [Full Text] [Related]  

  • 39. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid.
    Wilson SE; Solomkin JS; Le V; Cammarata SK; Bruss JB
    Am J Surg; 2003 Apr; 185(4):369-75. PubMed ID: 12657392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".
    Morata L; Mensa J; Soriano A
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6413-4. PubMed ID: 24222609
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.